Loading
GenFleet Therapeutics
GenFleet discovered fulzerasib, the first KRAS G12C inhibitor approved in China, and licensed it to Innovent for the Chinese market.
Also called: 劢维医药Genfleet Therapeutics (Shanghai)GenFleet Therapeutics
Overview
GenFleet Therapeutics, based in Shanghai and founded in 2017, discovered fulzerasib, the first KRAS G12C inhibitor approved in China, and licensed it to Innovent for the Chinese market. Fulzerasib, also GFH925 and sold as Dupert, was approved in August 2024, and combination trials with cetuximab are running. Its oral KRAS G12D inhibitor GFH375 is partnered with Verastem as VS-7375, and a pan-RAS inhibitor, GFH276, reached first clinical results in 2026. OnCo links it to fulzerasib, GFH375, Innovent Biologics and Verastem Oncology. Whether a Chinese-discovered KRAS inhibitor can compete in the West through a partner is the open question. Fulzerasib has its own page. GenFleet listed on the Hong Kong Stock Exchange in September 2025, raising gross proceeds of US$233 million.
Headquarters
Shanghai, CN
Scorecard
All companies#242of 1520 companies, score 21
- approved products +6
- phase 3 +3
- targets +2
- modalities +2
- regions +1
- registry trials +7
1 approved, 1 in phase 3, 0 earlier, 1 targets, 13 registry studies. Formula on the scorecards page.
Funding
All startupsInvestors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| IPO · Hong Kong Stock Exchange listing under the Chapter 18A biotech rules; gross proceeds as stated by Sullivan & Cromwell | 2025 | $233M | sullcrom.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Website
Founded
2017
Products
2ApprovedSmall-molecule covalent KRAS G12C inhibitor
Fulzerasib · Dupert
Fulzerasib was the first KRAS G12C-blocking pill approved in China, for lung cancers carrying that mutation after earlier treatment.
Phase 3small molecule (structure undisclosed or not yet in PubChem)
GFH375 is an experimental small-molecule drug from Genfleet Therapeutics (Shanghai) in phase 3 trials for pancreatic ductal adenocarcinoma and non-small-cell lung cancer, aimed at KRAS.
Notes
- Checked 29 October 2026. The earlier text called VS-7375 (GFH375) a KRAS G12C programme; GenFleet's own news and the GFH375 record describe it as a KRAS G12D inhibitor, so that was corrected. The Hong Kong listing is confirmed by the sponsor's counsel, Sullivan & Cromwell, and by the listing documents section of GenFleet's investor site; the stock code was not stated on the pages read, so no ticker is recorded. No acquisition was found.
Connected
19Similar pages
- PersonMichael Yu (Yu De-Chao)
Shares Fulzerasib, Innovent Biologics and the tag china.
- CompanyIASO Biotherapeutics
Shares Innovent Biologics and the tag china.
- TrialFUMANBA-1
Shares Innovent Biologics and the tag china.
- TrialORIENT-16
Shares Innovent Biologics and the tag china.
- TrialORIENT-32
Shares Innovent Biologics and the tag china.
- TrialORIENT-11
Shares Innovent Biologics and the tag china.
- TreatmentEquecabtagene autoleucel
Shares Innovent Biologics and the tag china.
- TreatmentSintilimab
Shares Innovent Biologics and the tag china.
fronts
drugs
ApprovedSmall-molecule covalent KRAS G12C inhibitor
Fulzerasib · Dupert
Phase 3small molecule (structure undisclosed or not yet in PubChem)
companies
trials
A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid TumorsA Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or MetastA Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid TumorsA Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCLA Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS MutationA Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D MutationA Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D MutationsA Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D MutationEfficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung CancerPhase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
genfleet.com · 1
sullcrom.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-18 · Jude Gomila · Merge worktree-agent-a5382dd3e7ef16308 (backlinks round) · diff · file
Sourced, not expert-reviewed